New drug gecacitinib tested for tough transplant complication
NCT ID NCT07476872
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called gecacitinib in 33 adults who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant and whose condition hasn't improved with steroids. The goal is to find a safe dose and see if it helps control the disease. Participants take the drug daily for 28 days or longer, and researchers monitor side effects and response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gecacitinib
- What this could lead to
- If successful, this could offer a new treatment option for people with chronic graft-versus-host disease that doesn't respond to steroids.
- What could go wrong
- This is an early-phase trial with only 33 participants, so results may not apply to everyone. The drug may cause side effects or fail to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody cocktail targets stubborn liver disease after stem cell transplants
- New drug combo aims to tame transplant complication
- New study aims to predict hidden hepatitis b danger in transplant patients
- Arthritis drug repurposed to fight stem cell transplant complication
- New combo therapy aims to tame chronic GVHD
- New study tracks 1,500 transplant patients to unlock secrets of a devastating complication